Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $0.76, $0.14 better than the analyst estimate of $0.62. Revenue for the quarter came in at $638 million versus the consensus estimate of $617.59 million.

Company reiterates full-year 2018 total CF product revenue guidance of $2.65 to $2.80 billion and combined non-GAAP R&D and SG&A expense guidance of $1.50 to $1.55 billion-

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.